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ABSTRACT 
Background: Theileriosis is a tick-borne disease caused by Theileria strains of the protozoan species. Buparvaquone is 
the mostly preferred drug in the treatment theileriosis, while it is safety in sheep, has not been detailed investigated. It has 
been hypothesized that buparvaquone may show side effects and these effects may be defined some parameters measured 
from blood in sheep when it is used at the recommended dose and duration. The aim of this research was to determine the 
effect of buparvaquone on the blood oxidative status, cardiac, hepatic and renal damage and bone marrow function markers.
Materials, Methods & Results: In this study, ten adult (> 2 years) Akkaraman rams were used. Healthy rams were placed 
in paddocks, provided water ad libitum, and fed with appropriate rations during the experiment. Buparvaquone was ad-
ministered at the dose of 2.5 mg/kg (IM) intramuscularly twice at 3-day intervals. Blood samples were obtained before 
(0. h, Control) and after drug administration at 0.25, 0.5, 1, 2, 3, 4 and 5 days. The blood samples were transferred to gel 
tubes, and the sera were removed (2000 g, 15 min). During the study, the heart rate, respiratory rate, and body temperature 
were measured at each sampling time. In addition, the animals were clinically observed. Plasma oxidative status mark-
ers (Malondialdehyde, total antioxidant status, catalase, glutathione peroxidase, superoxide dismutase), serum cardiac 
(Troponin I, creatine kinase-MBmass, lactate dehydrogenase), hepatic (Alkaline phosphatase, alanine aminotransferase, 
aspartate aminotransferase, gamma glutamyltransferase, total protein, albumin, globulin) and renal (Creatinine, blood urea 
nitrogen) damage markers and hemogram values (white blood cell, red blood cell, platelet, hemogram, hematocrit) were 
measured. Buparvaquone caused statistically significantly (P < 0.05) increases in the troponin I and blood urea nitrogen 
levels and fluctuations in alkaline phosphatase activity, but there was no any statistically significance difference determined 
in the other parameters.
Discussion: In this study, buparvaquone was administered two times at a dose of 2.5 mg/kg (IM) at 3-day intervals. Al-
though the result was not statistically significant (P > 0.05), it was determined that buparvaquone gradually increased the 
levels of the main oxidative stress marker, MDA, by approximately 2.8 fold. CAT and GPX levels were also found to have 
decreased by 2.2 fold. Buparvaquone may cause lipid peroxidation by producing free radicals. Some other antiprotozoal 
drugs may affect the oxidative status and may increase MDA level and decrease SOD level. In this study, MDA, which is 
an indicator of lipid peroxidation in vivo, was used to partially detect developing lipid peroxidation. Changes in the levels 
of reduced GPX and CAT enzymes could be attributed to their use in mediating the hydrogen peroxide detoxification 
mechanisms. The absence of significant changes in the TAS levels in this study suggests that buparvaquone may partially 
induce oxidative stress by producing hydrogen peroxide, but no significant changes occurred in the oxidative stress level 
because of the high antioxidant capacity of sheep. In this study, buparvaquone caused a statistically significant increase 
(P < 0.05) in the level of Tn-I, which is a marker of specific cardiac damage (P < 0.05), whereas there was no statistically 
(P > 0.05) significant increase in CK-MBmass. Tn-I and CK-MB levels, which are used to define heart damage in humans, 
have been successfully used to determine heart damage in sheep. In this research study, the statistically significant increases 
in Tn-I but not CK-MBmass levels could be considered indicative of mild cardiac damage.
Keywords: ram, buparvaquone, safety.
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INTRODUCTION
Theileriosis is a tick-borne disease caused by 
Theileria species. Ovine theileriosis is an important 
parasitic disease, especially in tropical and subtropical 
regions [27]. Buparvaquone is the most important drug 
used in the treatment of theileriosis [13,27]. Although 
some studies have shown that buparvaquone does not 
have carcinogenic, mutagenic, or teratogenic effects 
[17], no directly safety studies have been reported in 
the animals.
Antiprotozoal drugs may affect the oxida-
tive status [5]. Malondialdehyde (MDA) is the main 
biological marker of lipid peroxidation in oxida-
tive stress [6,12,20,24]. Reactive oxygen species 
(ROS) are targeted for inactivation by antioxidants 
[glutathione peroxidase (GPX), catalase(CAT), su-
peroxide dismutase (SOD)] in living cells [19,30]. 
The total antioxidant status (TAS) measured in 
biological materials describes the total activity 
of antioxidant substances against free radicals in 
vivo [10,25].
Drugs used at the prescribed dose and 
duration of treatment may cause side effects [3]. 
Troponin I (TnI), creatine kinase-MB (CK-MB)
mass, lactate dehydrogenase (LDH) and aspartate 
aminotransferase (AST) levels are used to deter-
mine cardiac damage [9,15,29]. The alanine ami-
notransferase (ALT), gamma glutamyltransferase 
(GGT), AST and proteins levels are measured as 
indicators of liver damage, while alkaline phospha-
tase (ALP) activity is used to determine bile duct 
damage. Blood urea nitrogen (BUN) and creatinine 
concentrations are affected by changes in renal 
function [14,28]. 
In this study it was aimed to determine the 
effect of buparvaquone on parameters of blood oxida-
tive status, the heart, liver, kidney, and bone marrow 
function.
MATERIALS AND METHODS
Animals and experimental procedure
In this study, ten adult (> 2 years) Akkara-
man rams were used. Healthy rams were placed 
in paddocks, provided water ad libitum, and fed 
with appropriate rations during the experiment. 
Buparvaquone was administered at a dose of 2.5 
mg/kg intramuscularly twice at 3-day intervals. 
Blood samples were obtained before (0 h, control) 
and 0.25, 0.5, 1, 2, 3, 4, and 5 days after drug ad-
ministration. The blood samples were transferred 
to gel tubes, and the sera were removed (2000 g, 
15 min). During the study, the heart rate, respira-
tory rate, and body temperature were measured at 
each sampling time. In addition, the animals were 
clinically observed. 
Measurements
MDA (MDA-586 Kit)1, TAS (Total Antioxi-
dant Status Kit)2, SOD (Superoxidase Dismutase 
Assay Kit)3, GPX (Glutathione Peroxidase Assay 
Kit)3 and CAT (Catalase Assay Kit)3 were deter-
mined using ELISA reader (MWGt Lambda Scan 
200)4 according to the kit procedure. The serum 
CK-MB and Tn-I levels were measured using a 
chemiluminescent immunoassay (Advia Centaur 
XP)5 while LDH, ALP, ALT, AST, GGT, total pro-
tein, albumin, globulin, BUN, and creatinine con-
centrations were measured using an autoanalyzer 
(ILAB-300)6. Hemogram tests (white blood cell, 
red blood cell, platelet, hemoglobin, hematocrit) 
of heparinized blood samples were performed us-
ing a blood cell counting device (BC-2800 Auto 
Hematology)7.
Statistical analysis 
The results of the study were presented as mean 
± SE. Data were assessed by ANOVA and post hoc 
Tukey test (SPSS 22.0)8. A significance level of P < 
0.05 was considered statistically significant.
RESULTS
No negative clinical observations were de-
tected in the animals during the study. The effects of 
buparvaquone on plasma oxidative status parameters 
are presented in Figure 1 and Table 1, and the effects 
on organ damage markers are presented in Table 
2. The effects of Tn-I and CK-MB mass levels are 
shown in Figures 2 and 3. Buparvaquone caused a 
statistically significant (P > 0.05) increase in Tn-I 
and BUN levels and fluctuations in ALP activity. The 
effect of buparvaquone on vital (pulse, respiration 
rate, body temperature) and hemogram parameters is 
presented in Table 3. Buparvaquone caused statisti-
cally significant fluctuations in body heat and heart 
rate (P < 0.05).
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Figure 1. Effect of buparvoquone on the serum plasma malondialdehyde 
(µM) levels (mean ± SE, P > 0.05).
Figure 2. Effect of buparvoquone on the serum troponin I (ng/mL) levels 
(mean ± SE, P < 0.05). a,bWithin groups statistical significant. 
Figure 3. Effect of buparvoquone on the serum CK-MBmass (ng/mL) 
levels (mean ± SE, P > 0.05).
DISCUSSION
Buparvaquone is one of the most frequently 
used drugs in theileriosis treatment in the animals. 
Although no carcinogenic, mutagenic, and tera-
togenic effects have been observed with this drug 
[17] and the standard dose is accepted as safe, the 
European Medical Agency and the US Food and 
Drug Administration do not provide detailed safety 
information in the animals. The use of buparvaquone 
is recommended as an extra-label treatment for thei-
leriosis in sheep [31].
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In this study, buparvaquone was administered 
two times at a dose of 2.5 mg/kg (IM) at 3-day intervals. 
Although the result was not statistically significant (P 
> 0.05), it was determined that buparvaquone gradually 
increased the levels of the main oxidative stress marker, 
MDA, by approximately 2.8 fold (Figure 1). CAT and 
GPX levels were also found to have decreased by 2.2 
fold (Table 1). It has been reported that buparvaquone 
may cause lipid peroxidation by producing free radi-
cals [18]. Some other antiprotozoal drugs have been 
reported to affect the oxidative status [5] and may 
increase MDA level [1,11,16] and decrease SOD level 
[5]. In this study, MDA (Figure 1), which is an indicator 
of lipid peroxidation in vivo [24], was used to partially 
detect developing lipid peroxidation. Changes in the 
levels of reduced GPX and CAT enzymes (Table 1) 
could be attributed to their use in mediating the hy-
drogen peroxide detoxification mechanisms [26,30]. 
The absence of significant changes in the TAS levels 
in this study (Table 1) suggests that buparvaquone may 
partially induce oxidative stress by producing hydrogen 
peroxide, but no significant changes occurred in the 
oxidative stress level because of the high antioxidant 
capacity of sheep. 
In this study, buparvaquone caused a statisti-
cally significant increase (P < 0.05) in the level of 
Tn-I (Figure 2), which is a marker of specific cardiac 
damage (P < 0.05), whereas there was no statistically 
(P > 0.05) significant increase in CK-MBmass. It has 
been determined that antiprotozoal drugs may increase 
Tn-I and CK-MB levels [4]. Tn-I, a troponin subtype, 
is the most specific marker used clinically to diagnose 
heart damage [21] and increases in circulating levels 
are observed within 4-6 h after damage [9,15,29]. The 
CK-MB level peaks within 24 h after damage and 
falls to normal levels within 3 days. TnI and CK-MB 
levels increase simultaneously in heart damage and 
are used as primer markers in the diagnosis of acute 
myocardial damage [9]. Tn-I and CK-MB levels, which 
are used to define heart damage in humans, have been 
reported to be successfully used to determine heart 
damage in sheep. Furthermore, experimental studies 
conducted in sheep determined that the heart failure 
markers (Troponin I, CK-MB) increased in the first 
6 h after administration [4,7]. In this research study, 
the statistically significant increases in Tn-I but not 
CK-MBmass levels could be considered indicative 
of mild cardiac damage. Furthermore, we determined 
that buparvaquone caused statistically (P < 0.05) 
significant changes in the reference values of the BUN, 
ALP (Table 2), pulse, and body temperature (Table 3) 
[2,22,23]. It has been reported that antiprotozoal drugs 
cause changes in the cardiac, liver, renal function, 
and hemogram parameters in sheep compared to the 
reference values [4,5,8].
CONCLUSIONS 
The present result suggests that the administra-
tion of buparvaquone at the prescribed doses and dura-
tion in rams does not have significant adverse effects 
on the oxidative status, heart, liver, and kidney damage 
markers as well as on hemogram parameters. However, 
we propose that it is necessary to pay attention to po-
tential heart and kidney damage, especially in seriously 
diseased animals or when used prolonged usage.
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